SIT Laboratorio Farmaceutico acquires POTASION from Sanofi 

SIT Laboratorio Farmaceutico (hereafter “SIT”) is pleased to announce the acquisition of Potasion brand from Sanofi, as a result of the agreement signed on November 8, 2022. 

The product is indicated for the treatment of potassium deficiency conditions, caused by the treatment with medicines such as diuretics, corticosteroids, and laxatives. 

Potasion is also indicated in those cases of potassium losses caused by digestive and renal disorders (including diarrhoea, vomiting, and hyperaldosteronism). 

Additional clinical uses of the drug are related to potassium supplementation in poisoning due to Digitalis, familial hypokalemic periodic paralysis, and in surgical patients. 

The acquisition of Potasion enhance our presence in Spain market by SIT’s Spanish affiliate DESMA Laboratorio Farmacéutico, which already include in its Spanish portfolio well-known brands in different therapeutic areas like Akineton, Hemicraneal and Proctolog. 

SIT is an Italian based pharmaceutical group with presence in 50 countries which develops, produces and commercializes more than 75 branded pharmaceutical products, Medical Devices and Food supplements. 

About SIT Laboratorio Farmaceutico 

SIT Group is a family-owned international pharmaceutical company, based in Italy since 1927, and today is an international pharmaceutical group with more than 90 years of experience and a recent history of prestigious acquisitions and global expansion. SIT Group is a reliable preferred acquirer for pharma businesses choosing to divest their “mature,” “established” or “tail” off-patent branded medicines. 

In its manufacturing plants, SIT continue the high-quality manufacturing and management of the medicines, aspiring to breathe new life into medicines, investing in them to renew the lifecycle and give new stability and sustainability over the long-term. For more information please visit